Records containing: HPV Infections
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-02-02Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer
-
CLINICAL_TRIALS study record update · 2026-01-21Cervical Cancer Screening of Postmenopausal Women in Low- and Middle-income Countries Using HPV Self-sampling and Triage by Genotyping and Cytology
-
CLINICAL_TRIALS study record update · 2025-07-23Phase 1 Study to Assess the Safety and Exploratory Immunogenicity of PV-001
-
CLINICAL_TRIALS study record update · 2025-03-03Evaluation of Tolerability and Immunogenicity of GARDASIL in Healthy Females, Between 16 and 26 Years of Age, in India.
-
CLINICAL_TRIALS study record update · 2024-11-04PREPAP Study: Tolerance and Effectiveness of the Monoterpenoid Zinc Tetra-ascorbo-camphorate (C14) on the Genital Load of Oncogenic HPV (HR-HPV) and Precancerous Cervical Lesions: Research With Direct Individual Benefit
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2024-04-17Evaluating the Immunogenicity and Safety of 9-valent Human Papillomavirus(Type6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine in Chinese Females Aged 9 to 45 Years: A Phase 3, Open-label, Non-randomised Clinical Trial
-
CLINICAL_TRIALS study record update · 2024-04-17Evaluating the Immune Persistence of Recombination Quadrivalent HPV Vaccine (Type 6, 11, 16, 18) in Healthy Chinese Female Subjects Aged 9 to 45 Years: A Phase 3, Open-label, Non-randomized Clinical Trial
-
CLINICAL_TRIALS study record update · 2024-04-17Evaluating the Immunogenicity and Safety of Quadrivalent Human Papillomavirus Recombinant Vaccine (Type 6, 11, 16, 18) in Healthy Chinese Female Subjects Aged 9 to 26 Years: A Phase 3, Open-label, Non-randomized Clinical Trial
-
CLINICAL_TRIALS study record update · 2023-11-24A Randomized, Double-Blind and Positive-Controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged16-26 Years
-
CLINICAL_TRIALS study record update · 2023-05-24Significance of the High-risk Hpv Viral Load
-
CLINICAL_TRIALS study record update · 2023-04-13A Randomized, Double-Blind and Placebo-Controlled Phase I Study to Evaluate the Safety and Immunogenicity of a 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Pichia Pastoris) in 9 to 45 Year Old Chinese Females
-
CLINICAL_TRIALS study record update · 2020-10-01A Phase IV, Randomised Study to Evaluate the Immune Responses of UK Adolescent Girls Receiving CervarixTM or GardasilTM Human Papillomavirus Vaccines
-
CLINICAL_TRIALS study record update · 2018-09-14A Randomized, Double-Blind and Placebo-Controlled Phase I Study to Evaluate the Safety and Primary Immunogenicity of the Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 9-45 Years
-
CLINICAL_TRIALS study record update · 2018-04-05Crossover Vaccination of Women Previously Randomized Into Protocol 04-C-N191(NCI)/IC-200403(INCIENSA)
-
CLINICAL_TRIALS study record update · 2017-10-12A Randomized, Placebo-Controlled, Double-Blind Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine to Investigate the Safety, and Efficacy in Chinese 20 - to 45-Years-Old Women
-
CLINICAL_TRIALS study record update · 2015-01-13A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (9 to 15 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds)
-
CLINICAL_TRIALS study record update · 2012-03-20Prevalence of HPV Genotypes in Genital Warts in Colombian Male and Female Population Attending Medical Services.
-
CLINICAL_TRIALS study record update · 2011-08-05Biomarkers of HPV Clearance: A Prospective Study
-
CLINICAL_TRIALS study record update · 2010-08-18V501 Phase II Immunogenicity Study in Females Aged 9 to 17 Years
-
CLINICAL_TRIALS study record update · 2010-06-29V501 Phase II Efficacy Study in Women Aged 18 to 26
-
CLINICAL_TRIALS study record update · 2009-11-30ClinicalTrials.gov study NCT01021904
-
CLINICAL_TRIALS study record update · 2009-08-20An Open-Label, Single-Dose, Safety and Tolerability Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Chinese Female Subjects Aged 9 to 26 Years